Skip to main content
News Icon

News categories: Publication

CRC for Brown and Beige Fat Organ Crosstalk, Signaling and Energetics

Prof. Dr. med. Alexander Pfeifer becomes speaker of the newly founded Collaborative Research Center for Brown and Beige Fat Organ Crosstalk, Signaling and Energetics

Worldwide, the number of overweight and obese patients is increasing, and consequently diabetes and cardiovascular disease. Obesity is also a risk factor for developing severe Covid19. In the Transregional Collaborative Research Centre (CRC) 333 "Brown and Beige Fat Organ Crosstalk, Signaling and Energetics ( BATenergy)", researchers from the University of Bonn and the University Hospital Bonn, the University Medical Center Hamburg-Eppendorf (UKE), the Technical University of Munich (TUM) and the Helmholtz Zentrum München are investigating different types of adipose tissue and their role in metabolic diseases. As speaker of the CRC, Prof. Dr. med. Alexander Pfeifer, member of ImmunoSensation2 and head of the institute of Pharmacology and Toxicology at the University Clinics Bonn, was appointed.

The CRC’s research focus lies on brown fat cells, which are specialized in converting energy into heat. This makes them fundamentally different from white fat cells, which store energy in the form of fat. But even in white adipose tissue there are isolated brown fat cells, called "beige" cells. The goal of the CRC is to characterize the function of brown adipose cells at all levels, to uncover new communication pathways within our body, and thus to develop new therapeutic approaches for metabolic diseases in the future.

Brown adipose tissue is activated by cold. The researchers want to identify the body's own messenger substances and find out how different organs regulate brown fat. "This will provide a new picture of mutual communication of adipose tissue with other metabolic organs," says Prof. Dr. Alexander Pfeifer.

In their projects, the teams use state-of-the-art molecular biology methods as well as cell culture systems of fat cells and investigate metabolism from mice to humans. In this way, they hope to uncover new molecular mechanisms and target structures for drugs. On the long term, this should lead to new therapeutic approaches for the treatment of metabolic disease.

The vice speakers Prof. Dr. Jörg Heeren from the Institute of Biochemistry and Molecular Cell Biology of the UKE and Prof. Dr. Henriette Uhlenhaut from the TUM School of Life Sciences emphasize that the CRC uniquely brings together expert teams from metabolism research at three German Universities of Excellence and the Helmholtz Zentrum in Munich.

The CRC is thematically embedded in the Transdisciplinary Research Areas "Life and Health" and "Sustainable Futures" of the University of Bonn. At the UKE, the CRC is thematically assigned to the interdisciplinary research area C3I (Center for Inflammation, Infection and Immunity).

Contact

Prof. Dr. med. Alexander Pfeifer

Institute of Pharmacology and Toxicology

University of Bonn

Phone: +49-228-287-51300/51302

Email: alexander.pfeifer@uni-bonn.de

Related news

Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

News categories: Publication

The Gut as a Key Player in Immunotherapy for MS

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry
Dr. Ivana Jorgacevic und Prof. Dr. Rayk Behrendt have discovered that the inflammatory messenger substance interferon-alpha can trigger Sjögren's syndrome: The researchers in Bonn.

News categories: Publication

New test points to precision treatment for autoimmune condition

Interferon alpha is an inflammatory mediator that can cause Sjögren’s syndrome, an autoimmune disease. This is revealed in a recent study carried out by the University Hospital Bonn together with the University of Bonn, the University of Edinburgh and Newcastle University. Their findings, which have been published in the journal “Lancet Rheumatology,” could make it easier in the medium term to develop drugs to fight this chronic condition.
View entry

Back to the news overview